Репозиторий Университета

© Bionika Media Ltd. Objective. To investigate the clinical efficacy of Elgyna in the medical treatment of human papillomavirus (HPV)- associated cervical intraepithelial neoplasias (CIN). Subject and methods. The results of antibacterial therapy prior to destructive treatment were comparatively analyzed in 53 patients with severe dysbiosis in HPV-associated CIN. A study group included 27 patients who took the combined drug Elgyna as one vaginal tablet twice daily (6 administrations); a comparison group of 27 patients received the combined drug Tergynan as one vaginal tablet twice daily (6 administrations). A control group comprised 20 women with the visually unchanged cervix. All the women underwent standard examinations and vaginal microbiocenosis estimation by RT-PCR assay using the Femoflor test. Results. The use of the combined drug Elgyna during medical treatment before destruction was found to normalize molecular biological parameters at the local level and contributes to a significant reduction in the time of epithelialization and a decline in the number of recurrences. Conclusion. HPV-associated cervical neoplasias are accompanied by the development of pronounced dysbiotic processes in the vagina with the predominant involvement of obligate anaerobes. Taking into account the properties of the combined drug Elgyna that provides a normalizing effect on the parameters of biocenosis in accelerating healing and in preventing a recurrence of the process, it is appropriate to prescribe the drug before destructive treatments.

© 2018, Bionika Media Ltd.. All rights reserved. Objective. To improve cervical cancer screening programs via clinical introduction of a diagnostic vaginal swab self-sampling test for the detection of high-risk human papillomavirus (hrHPV). Subjects and methods. A total of 455 residents of the Lipetsk Region were examined; vaginal swabs tested for HPV were taken both independently by a woman with a Qvintip device and by a gynecologist with a universal urogenital probe. The women were asked whether it was convenient for them to self-collect a vaginal swab. Results. In the surveyed sample of 455 women, there were 35 (7.7%) cases of hrHPV identified on the swabs collected by the Qvintip and 38 (8.4%) women with hrHPV detected on those taken by the physician, out of them 26 (68.5%) women had atypical squamous cells of undetermined significance. 70.3% of women preferred the Qvintip self-sampling method. Conclusion. The Qvintip self-sampling method for hrHPV testing shows high diagnostic efficiency, simplicity, and ease-to-use. The method may be recommended for the detection of hrHPV to increase cervical cancer screening coverage.